Pro-Tmune, The Next Generation Graft For Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety And Efficacy Data

ProTmune, an ex vivo modulated mobilized peripheral blood (mPB) graft, has FDA fast track designation for the reduction of incidence and severity of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Despite the use of standard protocols to prevent its occurrence, 50 to 60% of patients receiving an unrelated allogeneic HCT experience acute GvHD within 60 days post-HCT.